GlassScriptPhysician profile
Julio C Paez
NPI 1447246525
$8,752.71
in general payments reported to CMS, 2019-2025
50 companies · $1,725 in 2025
The $1,725 reported for 2025 was more than what 79% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,143 · 2020: $361 · 2021: $431 · 2022: $1,075 · 2023: $1,834 · 2024: $2,184 · 2025: $1,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,743.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,734.32 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, General - Therapies |
| Abbvie INC. | $493.07 | 2021-2024 | |
| Medtronic, INC. | $435.28 | 2022-2024 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Si-Bone, INC. | $406.68 | 2019-2024 | |
| Nevro Corp. | $387.41 | 2020-2024 | Senza |
| Scilex Pharmaceuticals INC. | $348.46 | 2019-2025 | Ztlido |
| Vertos Medical, INC. | $290.23 | 2021-2023 | Mild Device Kit |
| Protega Pharmaceutials INC | $260.93 | 2022-2025 | Roxybond |
| Stimwave Technologies Incorporated | $228.20 | 2019-2020 | |
| Foundation Fusion Solutions, LLC | $209.78 | 2024 | |
| Collegium Pharmaceutical, INC. | $165.09 | 2019-2021 | |
| Stryker Corporation | $164.45 | 2025 | Mild Device Kit |
| Amgen INC. | $153.18 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $142.56 | 2019-2020 | |
| Pfizer INC. | $130.93 | 2019-2024 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $92.97 | 2019-2023 | Amyvid |
| Zyla Life Sciences, INC. | $81.80 | 2019-2020 | |
| Abbott Laboratories | $79.81 | 2023-2025 | Proclaim, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.73 | 2023-2025 | Relistor |
| Ibsa Pharma INC. | $73.98 | 2023-2025 | Tirosint, Licart, Tirosint |
| Averitas Pharma INC. | $62.55 | 2024 | Qutenza |
| Flowonix Medical Incorporated | $50.87 | 2019 | |
| Azurity Pharmaceuticals, INC. | $48.18 | 2023 | Horizant |
| Nalu Medical, INC. | $47.33 | 2021-2024 | Nalu Neurostimulation System |
| Arbor Pharmaceuticals, INC. | $42.93 | 2019-2020 | |
| Allergan, INC. | $41.31 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $40.00 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.62 | 2022 | |
| Radius Health, INC. | $39.24 | 2019 | |
| Zavation Medical Products, LLC | $36.70 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.29 | 2022 | |
| Biogen, INC. | $32.60 | 2021-2023 | Spinraza |
| Idorsia Pharmaceuticals US INC | $29.05 | 2022-2023 | Quviviq |
| Saluda Medical Americas, INC. | $28.52 | 2024 | Evoke |
| Medtronic USA, INC. | $26.03 | 2019-2020 | |
| Ge Healthcare | $24.79 | 2022 | |
| Tersera Therapeutics LLC | $23.74 | 2019 | |
| Alnylam Pharmaceuticals INC. | $23.38 | 2022 | |
| Grt US Holding, INC. | $21.39 | 2021 | |
| Bioventus LLC | $20.68 | 2023 | Stimrouter Implantable Kit |
| Spr Therapeutics, INC | $18.35 | 2024 | Sprint Pns System |
| Painteq LLC | $17.51 | 2023 | Painteq |
| Trice Medical, INC. | $15.10 | 2024 | |
| Biodelivery Sciences International, INC. | $15.01 | 2021 | |
| Curonix LLC | $14.68 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Paez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.